Cargando…

Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

PURPOSE: The JFMC33-0502 trial is a phase III clinical study designed to determine the most appropriate duration of postoperative adjuvant chemotherapy with uracil–tegafur (UFT) plus leucovorin in patients with stage IIB or III colon cancer. We report the interim results of preplanned safety analyse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuchiya, Takashi, Sadahiro, Sotaro, Sasaki, Kazuaki, Kondo, Ken, Katsumata, Kenji, Nishimura, Genichi, Kakeji, Yoshihiro, Baba, Hideo, Morita, Takayuki, Koda, Keiji, Sato, Seiji, Matsuoka, Junji, Yamaguchi, Yoshiyuki, Usuki, Hisashi, Hamada, Chikuma, Kodaira, Susumu, Saji, Shigetoyo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032639/ https://www.ncbi.nlm.nih.gov/pubmed/24744162 http://dx.doi.org/10.1007/s00280-014-2461-5

Ejemplares similares

Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502
por: Sadahiro, S., et al.
Publicado: (2015)

Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201)
por: Sadahiro, Sotaro, et al.
Publicado: (2022)

Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer
por: Suto, Takeshi, et al.
Publicado: (2017)

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study
por: Tomita, Naohiro, et al.
Publicado: (2019)

Administration Method of Adjuvant Tegafur‐Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study
por: Hata, Taishi, et al.
Publicado: (2021)

Cost-effectiveness of adjuvant chemotherapy with uracil–tegafur for curatively resected stage III rectal cancer
por: Hisashige, A, et al.
Publicado: (2008)

Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial
por: Hasegawa, Kiyoshi, et al.
Publicado: (2016)

Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials
por: Maeda, Hiromichi, et al.
Publicado: (2017)

Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial)
por: Okuno, Kiyotaka, et al.
Publicado: (2017)

Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer
por: Sadahiro, Sotaro, et al.
Publicado: (2017)

A case of successful concomitant administration of warfarin and uracil‐tegafur/leucovorin achieved by self‐measurement of INR
por: Watanabe, Norio, et al.
Publicado: (2017)

S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial
por: Watanabe, J., et al.
Publicado: (2021)

Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer
por: Kusumoto, Tetsuya, et al.
Publicado: (2018)

A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
por: Oki, E., et al.
Publicado: (2016)

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer
por: Huang, Wen-Yen, et al.
Publicado: (2017)

Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer
por: Yasui, Masayoshi, et al.
Publicado: (2006)

Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials
por: Aoyama, Toru, et al.
Publicado: (2017)

Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials
por: Aoyama, Toru, et al.
Publicado: (2017)

An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer
por: Sakamoto, J, et al.
Publicado: (2007)

Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer
por: Cellier, Patrice, et al.
Publicado: (2011)

Pathological Complete Response of Advanced Rectal Cancer Treated by Preoperative Chemoradiotherapy with Oral Tegafur-Uracil and Leucovorin: A Case Report
por: Wakasugi, Masaki, et al.
Publicado: (2013)

A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis
por: Kim, Sun Young, et al.
Publicado: (2017)

Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer
por: Alliot, C
Publicado: (2004)

Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer
por: Mayanagi, Shuhei, et al.
Publicado: (2018)

Complete Response of Pulmonary Metastases from Rectal Cancer to Tegafur-Uracil/Leucovorin plus Bevacizumab in an Elderly Patient: A Case Report
por: Shibutani, Masatsune, et al.
Publicado: (2018)

Tegafur–Uracil/Leucovorin Plus Oxaliplatin (TEGAFOX) as Consolidation Regimen after Short-Course Radiotherapy Is Effective for Locally Advanced Rectal Cancer
por: Liao, Chun-Kai, et al.
Publicado: (2022)

Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Kataria, Satya Pal, et al.
Publicado: (2022)

Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer
por: Ohwada, S, et al.
Publicado: (2004)

Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
por: Kotaka, Masahito, et al.
Publicado: (2015)

Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials
por: Honda, Michitaka, et al.
Publicado: (2017)

Tegafur-uracil-induced rapid development of advanced hepatic fibrosis
por: Honda, Shuya, et al.
Publicado: (2017)

Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan
por: Yu, Yen-Lin, et al.
Publicado: (2023)

Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study
por: Ohwada, S, et al.
Publicado: (2004)

A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
por: Li, C-P, et al.
Publicado: (2010)

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Ward, S E, et al.
Publicado: (2006)

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Almond, J, et al.
Publicado: (2007)

Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial
por: Abe, Shinya, et al.
Publicado: (2023)

Uracil-tegafur vs fluorouracil as postoperative adjuvant chemotherapy in Stage II and III colon cancer: A nationwide cohort study and meta-analysis
por: Chen, Po-Huang, et al.
Publicado: (2021)

Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis
por: Nakagawa, Ryosuke, et al.
Publicado: (2017)

Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
por: Sugimoto, Kiichi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s9o3n2730li267s9brentg3arv